Patents by Inventor Edmund V. Dennett, Jr.

Edmund V. Dennett, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230263733
    Abstract: Disclosed herein are solid oral dosage formulations comprising sodium sulfate, magnesium sulfate, and potassium chloride for inducing purgation of the colon of a subject. Furthermore, the disclosed compositions and formulations are useful to cleanse the colon when administered in sufficient quantities. Methods for inducing purgation of the colon and for cleansing the colon are also disclosed.
    Type: Application
    Filed: May 1, 2023
    Publication date: August 24, 2023
    Applicant: Braintree Laboratories, Inc.
    Inventors: Mark Cleveland, Edmund V. Dennett, JR., Russell W. Pelham
  • Publication number: 20230256010
    Abstract: Disclosed herein are solid oral dosage formulations comprising sodium sulfate, magnesium sulfate, and potassium chloride for inducing purgation of the colon of a subject. Furthermore, the disclosed compositions and formulations are useful to cleanse the colon when administered in sufficient quantities. Methods for inducing purgation of the colon and for cleansing the colon are also disclosed.
    Type: Application
    Filed: April 26, 2023
    Publication date: August 17, 2023
    Applicant: Braintree Laboratories, Inc.
    Inventors: Mark vB Cleveland, Edmund V. Dennett, JR., Russell W. Pelham
  • Patent number: 11638697
    Abstract: Disclosed herein are solid oral dosage formulations comprising sodium sulfate, magnesium sulfate, and potassium chloride for inducing purgation of the colon of a subject. Furthermore, the disclosed compositions and formulations are useful to cleanse the colon when administered in sufficient quantities. Methods for inducing purgation of the colon and for cleansing the colon are also disclosed.
    Type: Grant
    Filed: June 7, 2021
    Date of Patent: May 2, 2023
    Assignee: Braintree Laboratories, Inc.
    Inventors: Mark vB Cleveland, Edmund V. Dennett, Jr., Russell W Pelham
  • Patent number: 11382864
    Abstract: Disclosed herein are solid oral dosage formulations comprising sodium sulfate, magnesium sulfate, and potassium chloride for inducing purgation of the colon of a subject. Furthermore, the disclosed compositions and formulations are useful to cleanse the colon when administered in sufficient quantities. Methods for inducing purgation of the colon and for cleansing the colon are also disclosed.
    Type: Grant
    Filed: June 14, 2021
    Date of Patent: July 12, 2022
    Assignee: Braintree Laboratories, Inc.
    Inventors: Mark vB Cleveland, Edmund V. Dennett, Jr., Russell W Pelham
  • Publication number: 20210299050
    Abstract: Disclosed herein are solid oral dosage formulations comprising sodium sulfate, magnesium sulfate, and potassium chloride for inducing purgation of the colon of a subject. Furthermore, the disclosed compositions and formulations are useful to cleanse the colon when administered in sufficient quantities. Methods for inducing purgation of the colon and for cleansing the colon are also disclosed.
    Type: Application
    Filed: June 14, 2021
    Publication date: September 30, 2021
    Applicant: Braintree Laboratories, Inc.
    Inventors: Mark vB Cleveland, Edmund V. Dennett, JR., Russell W. Pelham
  • Publication number: 20210290546
    Abstract: Disclosed herein are solid oral dosage formulations comprising sodium sulfate, magnesium sulfate, and potassium chloride for inducing purgation of the colon of a subject. Furthermore, the disclosed compositions and formulations are useful to cleanse the colon when administered in sufficient quantities. Methods for inducing purgation of the colon and for cleansing the colon are also disclosed.
    Type: Application
    Filed: June 7, 2021
    Publication date: September 23, 2021
    Applicant: Braintree Laboratories, Inc.
    Inventors: Mark vB Cleveland, Edmund V. Dennett, JR., Russell W. Pelham
  • Patent number: 11033498
    Abstract: Disclosed herein are solid oral dosage formulations comprising sodium sulfate, magnesium sulfate, and potassium chloride for inducing purgation of the colon of a subject. Furthermore, the disclosed compositions and formulations are useful to cleanse the colon when administered in sufficient quantities. Methods for inducing purgation of the colon and for cleansing the colon are also disclosed.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: June 15, 2021
    Assignee: Braintree Laboratories, Inc.
    Inventors: Mark vB. Cleveland, Edmund V. Dennett, Jr., Russell W. Pelham
  • Publication number: 20200352855
    Abstract: Disclosed herein are compositions comprising a mixture of salts that induce purgation of the colon and are useful to cleanse the colon. Furthermore, the disclosed compositions can comprise a flavoring agent and polyethylene glycol. The disclosed compositions are superior to prior art compositions in that the disclosed compositions allow for higher tolerability, lower volumes, and improved patient compliance. In some embodiments, the composition comprises non-fermentable carbohydrates. Methods for inducing purgation of the colon and for cleansing the colon are also disclosed.
    Type: Application
    Filed: May 9, 2019
    Publication date: November 12, 2020
    Applicant: Sebela Pharmaceuticals, Inc.
    Inventors: Mark Cleveland, Edmund V. Dennett, JR., Russell W. Pelham, Matthew Walker
  • Publication number: 20190099375
    Abstract: Disclosed herein are solid oral dosage formulations comprising sodium sulfate, magnesium sulfate, and potassium chloride for inducing purgation of the colon of a subject. Furthermore, the disclosed compositions and formulations are useful to cleanse the colon when administered in sufficient quantities. Methods for inducing purgation of the colon and for cleansing the colon are also disclosed.
    Type: Application
    Filed: December 3, 2018
    Publication date: April 4, 2019
    Applicant: Braintree Laboratories, Inc.
    Inventors: Mark vB. Cleveland, Edmund V. Dennett, JR., Russell W. Pelham
  • Patent number: 10143656
    Abstract: Disclosed herein are solid oral dosage formulations comprising sodium sulfate, magnesium sulfate, and potassium chloride for inducing purgation of the colon of a subject. Furthermore, the disclosed compositions and formulations are useful to cleanse the colon when administered in sufficient quantities. Methods for inducing purgation of the colon and for cleansing the colon are also disclosed.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: December 4, 2018
    Inventors: Mark vB. Cleveland, Edmund V. Dennett, Jr., Russell W. Pelham
  • Publication number: 20180207200
    Abstract: The present invention is generally directed to an oral pharmaceutical tablet composition comprising a sulfate salt, for example, sodium sulfate, wherein the composition is capable of administration by direct oral ingestion and by disintegration in water prior to oral ingestion. The present invention is further directed to use of such oral pharmaceutical tablet formulations to induce laxation or to treat or prevent constipation.
    Type: Application
    Filed: January 31, 2018
    Publication date: July 26, 2018
    Applicant: Braintree Laboratories, Inc.
    Inventors: Edmund V. Dennett, JR., David S. Wells
  • Patent number: 9919007
    Abstract: The present invention is generally directed to an oral pharmaceutical tablet composition comprising a sulfate salt, for example, sodium sulfate, wherein the composition is capable of administration by direct oral ingestion and by disintegration in water prior to oral ingestion. The present invention is further directed to use of such oral pharmaceutical tablet formulations to induce laxation or to treat or prevent constipation.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 20, 2018
    Assignee: Braintree Laboratories, Inc.
    Inventors: Edmund V. Dennett, Jr., David S. Wells
  • Publication number: 20160030473
    Abstract: The present invention is generally directed to an oral pharmaceutical tablet composition comprising a sulfate salt, for example, sodium sulfate, wherein the composition is capable of administration by direct oral ingestion and by disintegration in water prior to oral ingestion. The present invention is further directed to use of such oral pharmaceutical tablet formulations to induce laxation or to treat or prevent constipation.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 4, 2016
    Inventors: Edmund V. Dennett, Jr., David S. Wells
  • Publication number: 20140087007
    Abstract: Disclosed is a method for rapidly cleansing the intestines and colon of a patient by orally administering an aqueous hypertonic sulfate solution, and then an aqueous isotonic solution to induce purgation, the purgations induced resulting in intestinal and colonic cleansing in less than four hours from the administration of the sulfate solution.
    Type: Application
    Filed: March 15, 2013
    Publication date: March 27, 2014
    Applicant: Braintree Laboratories, Inc.
    Inventors: Mark vB. Cleveland, Edmund V. Dennett, JR., John D. McGowan
  • Patent number: 7291324
    Abstract: Stimulant laxative in combination with an osmotic laxative produces safe and effective bowel and colon cleansing with a reduced volume of liquid input. Administering to a patient an oral stimulant laxative, such as bisacodyl, followed, after a biologically determined interval, by a reduced volume of a PEG in water solution cleanses the bowels and colon in preparation for diagnostic colonoscopy, without the profuse uncontrollable diarrhea that typically follows either ingestion of large volume isotonic ravages, or smaller volume hypertonic lavages.
    Type: Grant
    Filed: October 22, 2002
    Date of Patent: November 6, 2007
    Assignee: Braintree Laboratories Inc.
    Inventors: Edmund V. Dennett, Jr., Robert M. Raleigh, Jr., Mark V B. Cleveland, Russell W. Pelham
  • Patent number: 6875445
    Abstract: A composition for inhibiting gastrointestinal absorption of phosphorous in an individual. The composition includes a quantity of calcium acetate sufficient to bind the phosphorous in the gastrointestinal tract of the individual. The calcium acetate has a bulk density of between 0.50 kg/L and 0.80 kg/L and is dimensioned to form a caplet for fitting within a capsule in a manner that optimizes the volume of the capsule. Also provided is a method for administering the calcium acetate composition of the present invention to an individual to reduce phosphorous absorption by binding with the phosphorous in their gastrointestinal tract.
    Type: Grant
    Filed: October 24, 2002
    Date of Patent: April 5, 2005
    Assignee: Nabi Biopharmaceuticals
    Inventors: Edmund V. Dennett, Jr., Robert M. Raleigh, Jr., Bruce H. Aronson
  • Patent number: 6576665
    Abstract: A composition for inhibiting gastrointestinal absorption of phosphorous in an individual. The composition includes a quantity of calcium acetate sufficient to bind the phosphorous in the gastrointestinal tract of the individual. The calcium acetate has a bulk density of between 0.50 kg/L and 0.80 kg/L and is dimensioned to form a caplet for fitting within a capsule in a manner that optimizes the volume of the capsule. Also provided is a method for administering the calcium acetate composition of the present invention to an individual to reduce phosphorous absorption by binding with the phosphorous in their gastrointestinal tract.
    Type: Grant
    Filed: April 3, 2001
    Date of Patent: June 10, 2003
    Assignee: Braintree Laboratories, Inc.
    Inventors: Edmund V. Dennett, Jr., Robert M. Raleigh, Jr., Bruce H. Aronson